Nuclear Engineering and Technology

  • 제55권1호
  • /
  • Pages.254-260
  • /
  • 2023
  • /
  • 1738-5733(pISSN)
  • /
  • 2234-358X(eISSN)
한국원자력학회 (Korean Nuclear Society)
권호 표지
DOI QR코드

DOI QR Code

177Lu-EDTMP radiation absorbed dose evaluation in man based on biodistribution data in Wistar rats

  • Reza Bagheri (Northwest Research Complex (Bonab), Radiation Applications Research School, Nuclear Science and Technology Research Institute)
  • 투고 : 2022.03.25
  • 심사 : 2022.08.26
  • 발행 : 2023.01.25
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Skeletal metastases are common in patients suffering from various primary cancers. Radiopharmaceuticals are an effective option for bone pain palliation. In this work, the radiation absorbed dose of 177Lu-EDTMP radiopharmaceutical was estimated for adult man based on biodistribution data in Wistar rats. The MIRD dose calculation method and the Sparks and Aydogan methodology were applied. The results shows that about 46% of injected activity is cumulated on the surface of the trabecular and cortical bones. Radiation absorbed doses of red bone marrow and osteogenic cells were estimated to about 1.1 and 6.2 mGy/MBq, respectively. The maximum administrated activity was obtained 27 MBq/kg of body weight with an effective dose of 0.23 mSv/MBq. The results were compared with other available data from literature. This study indicated that 177Lu-EDTMP provides therapeutic efficacy for achieving bone pain palliation with low undesired dose to other normal organs.

키워드

과제정보

The author wishes to thank Ms. Michael G. Stabin from Department of Radiology and Radiological Sciences, Vanderbilt University, fur supplying the S-values for lutetium-177 radionuclide.

참고문헌

  1. A. Bahrami-Samani, R. Bagheri, A.R. Jalilian, S. Shirvani-Arani, M. Ghannadi-Maragheh, M. Shamsaee, Production, quality control and pharmacokinetic studies of 166Ho-EDTMP for therapeutic applications, Sci. Pharm. 78 (2010) 423-433. https://doi.org/10.3797/scipharm.1004-21
  2. S. Dalvand, M. Sadeghi, Bone marrow dosimetry for 141Ce-EDTMP as a potential bone pain palliation complex: a Monte Carlo study, Appl. Radiat. Isot. 182 (2022), 110113.
  3. Z. Bayat, E. Saeedzadeh, N. Vahidfar, M. Sadeghi, et al., Preparation and validation of [67Ga]Ga-phytate kit and Monte Carlo dosimetry: an effort toward developing an impressive lymphoscintigraphy tracer, J. Radioanal. Nucl. Chem. 331 (2022) 691-700. https://doi.org/10.1007/s10967-021-08183-z
  4. R. Bagheri, A.R. Jalilian, A. Bahrami-Samani, M. Mazidi, M. Ghannadi-Maragheh, Production of Holmium-166 DOTMP: a promising agent for bone marrow ablation in hematologic malignancies, Iran J. Nucl. Med. 19 (2011) 12-20.
  5. S.A. Sahafi-Pour, S.P. Shirmardi, E. Saeedzadeh, S. Baradaran, M. Sadeghi, Internal dosimetry studies of 177Lu-BBN-GABA-DOTA, as a cancer therapy agent, in human tissues based on animal data, Appl. Radiat. Isot. 186 (2022), 110273.
  6. F. Johari Daha, M. Shafiei, Sh. Sheibani, et al., Production of 177Lu and formulation of Ethylene diamine tetramethylene phosphonate (EDTMP) kits as a bone-seeking radiopharmaceutical, Iran, J. Radiat. Res. 7 (2010) 229-234.
  7. M. Tomblyn, The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases, Cancer Control. 19 (2012) 137-144. https://doi.org/10.1177/107327481201900208
  8. S.P. Shirmardi, E. Saniei, T. Das, M. Noorvand, et al., Internal dosimetry studies of 170Tm-EDTMP complex, as a bone pain palliation agent, in human tissues based on animal data, Appl. Radiat. Isot. 166 (2020), 109396.
  9. IAEA, Therapeutic Applications of Radiopharmaceuticals, IAEA, Vienna, 2001. TECDOC-1228.
  10. R. Bagheri, H. Afarideh, M. Ghannadi-Maragheh, A. Bahrami-Samani, S.P. Shirmardi, Dosimetric study of radium-223 chloride and 153Sm-EDTMP for treatment of bone metastases using MCNPX code and available experimental data, J. Radioanal. Nucl. Chem. 303 (2015) 1991-1998.
  11. S. Nilsson, R.H. Larsen, S.D. Fossa, et al., First clinical experience with a-emitting radium-223 in the treatment of skeletal metastases, Clin. Cancer Res. 11 (2005) 4451-4459. https://doi.org/10.1158/1078-0432.CCR-04-2244
  12. T. Das, S. Chakraborty, P.R. Unni, S. Banerjee, G. Samuel, H.D. Sarma, M. Venkatesh, M.R.A. Pillai, 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation, Appl. Radiat. Isot. 57 (2002) 177-184. https://doi.org/10.1016/S0969-8043(02)00104-5
  13. S. Chakraborty, T. Das, P.R. Unni, H.D. Sarma, G. Samuel, S. Banerjee, M. Venkatesh, N. Ramamoorthy, M.R.A. Pillai, 177Lu labelled polyaminophosphonates as potential agents for bone pain palliation, Nucl. Med. Commun. 23 (2002) 67-74. https://doi.org/10.1097/00006231-200201000-00011
  14. I.A. Abbasi, Preliminary studies on 177Lu-labeled sodium pyrophosphate (177Lu-PYP) as a potential bone-seeking radiopharmaceutical for bone pain palliation, Nucl. Med. Biol. 39 (2012) 763-769. https://doi.org/10.1016/j.nucmedbio.2012.02.001
  15. I.A. Abbasi, Studies on 177Lu-labeled methylene diphosphonate as potential bone-seeking radiopharmaceutical for bone pain palliation, Nucl. Med. Biol. 38 (2011) 417-425. https://doi.org/10.1016/j.nucmedbio.2010.09.013
  16. M.P. Yadav, S. Ballal, M. Meckel, F. Roesch, C. Bal, [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results, EJNMMI Res. 10 (2020) 1-13. https://doi.org/10.1186/s13550-019-0588-4
  17. S. Chakraborty, T. Das, H.D. Sarma, M. Venkatesh, S. Banerjee, Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis, Appl. Radiat. Isot. 66 (2008) 1196-1205. https://doi.org/10.1016/j.apradiso.2008.02.061
  18. T. Das, S. Chakraborty, H.D. Sarma, S. Banerjee, 177Lu-DOTMP: a viable agent for palliative radiotherapy of painful bone metastasis, Radiochim. Acta 96 (2008) 55-61. https://doi.org/10.1524/ract.2008.1464
  19. N. Bollampally, J. Shukla, B.R. Mittal, et al., Efficacy and safety of 177Lu-DOTMP in palliative treatment of symptomatic skeletal metastases: a prospective study, Nucl. Med. Commun. 42 (2021) 964-971. https://doi.org/10.1097/MNM.0000000000001425
  20. A. Bahrami-Samani, A. Anvari, A.R. Jalilian, et al., Production, quality control and pharmacokinetic studies of 177Lu-EDTMP for human bone pain palliation therapy trials, Iran, J. Pharm. Sci. 11 (2012) 137-144.
  21. J. Yuan, C. Liu, X. Liu, et al., Efficacy and safety of 177Lu-EDTMP in bone metastatic pain palliation in breast cancer and hormone refractory prostate cancer, Clin. Nucl. Med. 38 (2013) 88-92. https://doi.org/10.1097/RLU.0b013e318279bf4d
  22. A.S. Shinto, D. Shibu, K.K. Kamaleshwaran, et al., 177Lu-EDTMP for treatment of bone pain in patients with disseminated skeletal metastases, J. Nucl. Med. Technol. 42 (2014) 55-61. https://doi.org/10.2967/jnmt.113.132266
  23. M. Alavi, Sh. Omidvari, A. Mehdizadeh, A.R. Jalilian, A. Bahrami-Samani, Metastatic bone pain palliation using 177Lu-Ethylenediaminetetramethylene phosphonic acid, World J. Nucl. Med. 14 (2015) 109-115. https://doi.org/10.4103/1450-1147.157124
  24. K.K. Agarwal, S. Singla, G. Arora, C. Bal, 177Lu-EDTMP for palliation of pain from bone metastases in patients with prostate and breast cancer: a phase II study, Eur. J. Nucl. Med. Mol. Imaging 42 (2015) 79-88. https://doi.org/10.1007/s00259-014-2862-z
  25. C. Bal, G. Arora, P. Kumar, et al., Pharmacokinetic, dosimetry and toxicity study of 177Lu-EDTMP in patients: phase 0/I study, Curr. Radiopharm. 9 (2016) 71-84. https://doi.org/10.2174/1874471008666150313105000
  26. H. Balter, T. Victoria, T. Mariella, 177Lu-labeled agents for neuroendocrine tumor therapy and bone pain palliation in Uruguay, Curr. Radiopharm. 9 (2016) 85-93. https://doi.org/10.2174/1874471008666150313112620
  27. S. Sharma, B. Singh, A. Koul, B.R. Mittal, Comparative therapeutic efficacy of 153Sm-EDTMP and 177Lu-EDTMP for bone pain palliation in patients with skeletal metastases: patients' pain score analysis and personalized dosimetry, Front. Med. 4 (2017) 1-9.
  28. T. Das, S. Banerjee, Theranostic applications of lutetium-177 in radionuclide therapy, Curr. Radiopharm. 9 (2016) 94-101. https://doi.org/10.2174/1874471008666150313114644
  29. M. Mirkovic, Z. Milanovic, D. Stankovic, et al., Investigation of 177Lu-labeled HEDP, DPD, and IDP as potential bone pain palliation agents, J. Radiat. Res. Appl. Sci. 13 (2020) 27-36.
  30. J. Zaknun, C. Bal, P. Dupont, Pharmacokinetics and dosimetry of the bone-seeking agent 177Lu-EDTMP in patients with metastatic prostate cancer, J. Nucl. Med. 52 suppl1 (2011) 1748.
  31. S. Chakraborty, T. Das, Sh. Banerjee, et al., 177Lu-EDTMP: a viable bone pain palliative in skeletal metastasis, Cancer Biother. Radiopharm. 23 (2008) 202-213.
  32. M.J. Belanger, S.M. Krause, C. Ryan, S. Sanabria-Bohorquez, W. Li, T.G. Hamill, et al., Biodistribution and radiation dosimetry of 18F-PEB in nonhuman primates, Nucl. Med. Commun. 29 (2008) 915-919. https://doi.org/10.1097/MNM.0b013e3283060c72
  33. W.K.A. Louw, C. Domehl, A.J. van Rensburg, N. Hugo, A.S. Alberts, O.E. Forsyth, et al., Evaluation of samarium-153 and holmium-166-EDTMP in the normal baboon model, Nucl. Med. Biol. 23 (1996) 935-940. https://doi.org/10.1016/S0969-8051(96)00117-5
  34. W.E. Bolch, K.F. Eckerman, G. Sgouros, S.R. Thomas, MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature, J. Nucl. Med. 50 (2009) 477-484. https://doi.org/10.2967/jnumed.108.056036
  35. J.A. Siegel, Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry, Cancer Biother. Radiopharm. 20 (2005) 126-140.
  36. R.B. Sparks, B. Aydogan, Comparison of the effectiveness of some common animal data scaling techniques in estimating human radiation dose, in: Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge Associated Universities, Oak Ridge, TN, 1996, pp. 705-716.
  37. ICRP, ICRP Publication 23, Report of the Task Group on Reference Man, Pergamon Press, New York, 1975.
  38. J.M. Peters, E.M. Boyd, Organ weights and water levels of the rat following reduced food intake, J. Nutr. 90 (1966) 354-360. https://doi.org/10.1093/jn/90.4.354
  39. G. Miller, J.A. Klumpp, D. Poudel, W. Weber, R.A. Guilmette, J. Swanson, Americium systemic biokinetic model for rats, Radiat. Res. 192 (2019) 75-91. https://doi.org/10.1667/RR15256.1
  40. M.G. Stabin, R.B. Sparks, E. Crowe, OLINDA/EXM: the Second-generation personal computer software for internal dose assessment in nuclear medicine, J. Nucl. Med. 46 (2005) 1023-1027.
  41. ICRP, ICRP Publication 103, the 2007 Recommendations of the International Commission on Radiological Protection, ume 37, Elsevier, 2007.
  42. R. Bagheri, H. Afarideh, M. Ghannadi-Maragheh, S.P. Shirmardi, A. Bahrami-Samani, Study of bone surface absorbed dose in treatment of bone metastases via selected radiopharmaceuticals: using MCNP4C code and available experimental data, Cancer Biother. Radiopharm. 30 (2015) 174-181.
  43. R. Bagheri, A. Bahrami-Samani, M. Ghannadi-Maragheh, Estimation of radiation absorbed dose in man from 166Ho-EDTMP based on biodistribution data in Wistar rats, Radiat. Phys. Chem. 187 (2021) 1-6. https://doi.org/10.1016/j.radphyschem.2021.109560
  44. ICRP, ICRP Publication 89, Basic Anatomical and Physiological Data for Use in Radiological Protection: Reference Values, Pergamon Press, New York, 2002.
  45. M.L. Barlett, M. Webb, S. Durrant, A.J. Morton, R. Allison, D.J. Macfarlene, Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other hematological malignancies, Eur. J. Nucl. Med. 29 (2002) 1470-1477. https://doi.org/10.1007/s00259-002-0934-y
  46. H.B. Breitz, R.E. Wendt III, M.S. Stabin, S. Shen, W.D. Erwin, J.G. Rajendran, et al., 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy, J. Nucl. Med. 47 (2006) 534-542.
  47. F. Rosch, H. Herzog, C. Plag, B. Neumaier, U. Braun, H.W. Muller-Gartner, et al., Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography, Eur. J. Nucl. Med. 23 (1996) 958-966. https://doi.org/10.1007/BF01084371
  48. L. Vigna, R. Matheoud, S. Ridone, D. Arginelli, P. Della Monica, M. Rudoni, et al., Characterization of the [153Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis, Phys. Med. 27 (2011) 144-152. https://doi.org/10.1016/j.ejmp.2010.08.001
  49. M. Lyra, G. Papanikolos, P. Phinou, A.P. Frantzis, J. Jordanou, G.S. Limouris, Rhenium-186-HEDP dosimetry and multiple bone metastases palliation therapy effects, Radionuclide Ther. Oncol. Curr. Status Future Aspects 10 (2003) 51-60.
  50. K. Liepe, R. Hliscs, J. Kropp, R. Runge, F.F. Knapp Jr., W.G. Franke, et al., Dosimetry of 188Re-Hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases, J. Nucl. Med. 44 (2003) 953-960.